Asked by: Lord Brady of Altrincham (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many phase one inspectors were employed by the Medicines and Healthcare products Regulatory Agency in each January since 2019.
Answered by Will Quince
The following table shows the number of Good Clinical Practice inspectors who are trained to perform the inspections of phase I clinical trial units, who are members of the Medicines and Healthcare products Regulatory Agency (MHRA) Phase I Accreditation Scheme of this type during each January from 2019 to 2023
Year | Number of inspectors |
January 2023 | 5 (plus 1 inspector in training) |
January 2022 | 6 |
January 2021 | 7 |
January 2020 | 6 |
January 2019 | 6 |
Asked by: Lord Brady of Altrincham (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the standard time is for a coordinated response by MHRA for clinical trails; and what the performance has been against that standard in the last 12 months.
Answered by Will Quince
The standard time for the initial coordinated response from the Medicines and Healthcare products Regulatory Agency (MHRA) is 30 days from the date of receipt of a valid request for authorisation of a clinical trial. The average coordinated performance against the standard for the last 12 months between February 2022 to February 2023 inclusive was 43.96 days.
Asked by: Lord Brady of Altrincham (Conservative - Life peer)
Question to the Scotland Office:
To ask the Secretary of State for Scotland, whether the proposed deposit return scheme in Scotland requires notification to the World Trade Organization under the Technical Barriers to Trade procedure.
Answered by Lord Jack of Courance
At this stage, the Scottish Government has not raised a requirement for WTO notification with the UK Government.
Devolved Administrations are aware of WTO obligations and the need to fulfil transparency obligations at the WTO as necessary.
Asked by: Lord Brady of Altrincham (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the (a) average and (b) longest time taken by MHRA to evaluate a clinical trial was in each of the last five years for which data is available.
Answered by Will Quince
For the financial year 2018/19, the average time taken by the Medicines and Healthcare products Regulatory Agency (MHRA) to assess a clinical trial was 23.29 days. The longest time taken was 56 days. For the financial year 2019/20, the average time taken by the MHRA to assess a clinical trial was 23.47 days. The longest time taken was 56 days. For the financial year 2020/21, the average time taken by the MHRA to assess a clinical trial was 21.43 days. The longest time taken was 49 days. For the financial year 2021/22, the average time taken by the MHRA to assess a clinical trial was 27.58 days. The longest time taken was 68 days. For the financial year 2022/23 (April 2022 – February 2023 inclusive), the average time taken by the MHRA to assess a clinical trial was 42.78 days. The longest time taken was 146 days.
Asked by: Lord Brady of Altrincham (Conservative - Life peer)
Question to the Department for Environment, Food and Rural Affairs:
To ask the Secretary of State for Environment, Food and Rural Affairs, whether the Scottish Government has submitted a request for a United Kingdom Internal Market Act 2020 exemption to implement a deposit return scheme in Scotland.
Answered by Rebecca Pow
At the Inter-Ministerial Group for Environment, Food and Rural Affairs (IMG EFRA) on 6 March, UK Government ministers received a formal request setting out the scope and rationale for a UKIM exemption for the Scottish Government's deposit return scheme. It will now be considered by Ministers at the relevant Whitehall departments.
Asked by: Lord Brady of Altrincham (Conservative - Life peer)
Question to the Department for Education:
To ask the Secretary of State for Education, what steps his Department is taking to ensure that Muslim students unable to access the traditional student finance system are able to access an alternative, faith-compliant method; and what his planned timetable is for such a system becoming fully operable.
Answered by Michelle Donelan
I refer my hon. Friend, the member for Altrincham and Sale West, to the answer I gave in response to question 129057.
Asked by: Lord Brady of Altrincham (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the cost of each quality-adjusted life year added to 5 to 11 year old children as a result of offering that cohort a covid-19 vaccination.
Answered by Maggie Throup
On 22 December 2021, the Government accepted the advice of the Joint Committee on Vaccination and Immunisation (JCVI) to offer COVID-19 vaccinations to children aged five to 11 years old who are in a clinical risk group, or who are household contacts of the immunosuppressed. On 16 February 2022, the Government subsequently accepted the JCVI’s advice to offer vaccination of children aged five to 11 years old not in a clinical risk group. However, the size and characteristics of a potential future wave were uncertain at the time of the JCVI’s advice, therefore it was not possible to determine the cost per quality adjusted life years gained.
Asked by: Lord Brady of Altrincham (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 6 September 2021 to Question 38143 on Coronavirus: Research, what his timetable is for publication of the research funded by the National Institute for Health Research.
Answered by Maria Caulfield
Four of the eight projects have published at least one paper on their findings. We anticipate papers from the remaining four studies although we do not have a confirmed timetable for their publication.
Asked by: Lord Brady of Altrincham (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the relative benefits of administering covid-19 vaccinations via aspiration compared to intravenous injection.
Answered by Maggie Throup
The UK Health Security Agency (UKHSA) has not made this assessment. The UKHSA provides guidance on immunisation techniques in Chapter Four of the Green Book, which follows available evidence and international recommendations for the administration of vaccines. This is reviewed and updated regularly by the UKHSA and states that it is not necessary to aspirate the syringe after the needle is introduced into the muscle because there are no large blood vessels at the recommended injection sites.
In addition, the only licensed route of administration for COVID-19 vaccines is via intra-muscular injection into the preferred site, the deltoid muscle. No assessment has therefore been made for intravenous injection. Vaccinations are not administered into the vein as this would be potentially harmful.
Asked by: Lord Brady of Altrincham (Conservative - Life peer)
Question to the Department for Transport:
To ask the Secretary of State for Transport, what his planned timetable is for publication of the final report of the union connectivity review.
Answered by Chris Heaton-Harris
Sir Peter has published his Union Connectivity Review as of Friday the 26th of November, the Government thanks Sir Peter for his work and will respond to his recommendations in due course.